GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate
Firms could find themselves charged multiple US generic drug user fees if affiliates are not identified and ANDAs claimed.
You may also be interested in...
German healthcare company Fresenius SE & Co. pursues a second major international deal in less than year, as new CEO confirms interest in US generics firm Akorn.
As state attorneys general and Department of Justice move against generic manufacturers, plaintiffs’ firms have filed more than 90 antitrust suits on behalf of third party payers.
Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.